Zhen‐Wei Cai

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

Janeta Popovici-Müller, René M. Lemieux, Erin Artin et al. · ACS Medicinal Chemistry Letters · 2018 · 422 citations · Full text

Idh1 Mutant Cancers, Somatic Point Mutations, Somatic Variant +14

Discovery of <i>N</i>-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily

Gretchen M. Schroeder, Yongmi An, Zhen‐Wei Cai et al. · Journal of Medicinal Chemistry · 2009 · 276 citations · Full text

Orally Efficacious Inhibitor, Drug Target, Pharmacotherapy +21

Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

Zenon Konteatis, Erin Artin, Brandon Nicolay et al. · ACS Medicinal Chemistry Letters · 2020 · 174 citations · Full text

Mutant Isocitrate Dehydrogenase, High-grade Gliomas, Glioma +18

Discovery of Brivanib Alaninate ((<i>S</i>)-((<i>R</i>)-1-(4-(4-Fluoro-2-methyl-1<i>H</i>-indol-5-yloxy)-5-methylpyrrolo[2,1-<i>f</i>][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)

Zhen‐Wei Cai, Yongzheng Zhang, R. M. Borzilleri et al. · Journal of Medicinal Chemistry · 2008 · 141 citations · Full text

Pharmaceutical Science, Oral Bioavailability, L-alanine Prodrug 8 +20

Discovery and Preclinical Studies of (<i>R</i>)-1-(4-(4-Fluoro-2-methyl-1<i>H</i>-indol-5-yloxy)-5- methylpyrrolo[2,1-<i>f</i>][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an In Vivo Active Potent VEGFR-2 Inhibitor

Rajeev S. Bhide, Zhen‐Wei Cai, Yong‐Zheng Zhang et al. · Journal of Medicinal Chemistry · 2006 · 131 citations · Full text